Opus Point Partners Management
STML

Opus Point Partners Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Opus Point Partners Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-20,595
Closed -$176K – 72
2017
Q1 		$176K Buy
+20,595
New +$188K 0.13% 66
2015
Q4 		– Sell
-75,000
Closed -$662K – 66
2015
Q3 		$662K Hold
75,000
– – 0.37% 40
2015
Q2 		$883K Hold
75,000
– – 0.7% 38
2015
Q1 		$1.08M Buy
75,000
+4,600
+7% +$70.4K 0.91% 31
2014
Q4 		$1.2M Buy
+70,400
New +$1.02M 1.19% 29

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Opus Point Partners Management's STML Position: Q2 2017 in Review

Opus Point Partners Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2017, closing a stake of 20,595 shares — an estimated $176K sold.

Opus Point Partners Management first reported a position in STML in Q4 2014 and held it in 5 quarters. The position peaked at $1.2M in Q4 2014. 70 funds tracked by Wall St. Rank hold STML as of Q2 2017.

  • Opus Point Partners Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Opus Point Partners Management sold 20,595 Stemline Therapeutics, Inc. shares in Q2 2017, an estimated $176K.
  • Opus Point Partners Management first reported a position in Stemline Therapeutics, Inc. in Q4 2014 and held it in 5 quarters.
  • Opus Point Partners Management's Stemline Therapeutics, Inc. position peaked at $1.2M in Q4 2014.
  • 70 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2017.

Based on Opus Point Partners Management's 13F filing for Q2 2017, filed 14 Aug 2017.